NCT03290079View on ClinicalTrials.gov

Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

January 10, 2023

Study Completion Date

May 13, 2024

Conditions
Neuroendocrine TumorsNeuroendocrine CarcinomaNeuroendocrine Cancer
Interventions
DRUG

Pembrolizumab

200 mg Pembrolizumab by IV on Day 1 of each 3 week cycle.

DRUG

Lenvatinib

20 mg Lenvatinib by mouth every day of each 3 week cycle

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT03290079 - Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter